We are a digital neuroscience company developing software products and services to better understand, detect and treat conditions affecting brain health.
These developments represent a significant step forward in our collective mission to fight Alzheimer's disease and dementias. If these topics are relevant to your work, we would love to chat! Find out more here: https://t.co/VlRwIKV96p
At AAIC25, we will be presenting the poster "Sensitivity of Cognitive Outcome Measures to Plasma p-tau217 in Mild Cognitive Impairment in the AI-Mind study," by Alex Kaula. Sign up to be the first to download this research: https://t.co/s6lOAwHoxD
Check out our latest research at #AAIC25. This poster presents comprehensive data on the development of composite speech biomarkers, rigorously validated for use as a novel endpoint in MCI/AD clinical trials. Find out more: https://t.co/FvYNMRgTdV
Speech biomarkers for MCI/AD - presenting analytical and clinical validation in Dutch, Danish, German & Spanish! Discover the impact of our global validation research presented at AAIC 2025. Dive deeper: https://t.co/bGVHZaf99F
Ensuring Data Reliability in High-Frequency Remote Assessments: Sign up to be the first to receive our research and find out how we are building confidence in remote data collection: https://t.co/UGavx2VfTk
#AAIC2025#DigitalBiomarkers#Alzheimers#Psychometrics#ClinicalTrials
We're thrilled to announce! We're presenting 4 exciting posters at #AAIC25! ๐ง Discover our latest science and get the insights shaping #CNS drug development:
https://t.co/1qIsdXU0GP #Alzheimers#DigitalBiomarkers#ClinicalTrials
Sponsored by Biogen in collaboration with Apple, he study enrolled a representative sample of 23,004 participants across the United States and relied on Cambridge Cognition's CANTABยฎ platform for the core cognitive assessment. Read more here: https://t.co/U8cVMg7hr6
Michael Spilka shares his key takeaways from this year's #Schizophrenia International Research Society Congress, and the key findings on his poster presentations.
Read more: https://t.co/fQARYtJOPg
The selection of the right cognitive assessment isn't just a methodological choice; it's a foundational element that underpins the reliability and impact of your clinical trial data.
โก๏ธ Explore the factors to consider and the benefits of each approach: https://t.co/aTU9qcs1LS
New Mild Cognitive Impairment insights! ๐ก
Nick Taptiklis's #ADPD2025 poster reveals novel reaction time measures from CANTABยฎ PAL. Discover how timing-based data enhances understanding of MCI. Download now! โก๏ธ https://t.co/ywPuNRiveA
#MCI#Neuroscience#Alzheimers#Parkinsons
The ability to conduct reliable cognitive testing remotely is crucial for expanding access and efficiency in studies related to aging and neurodegenerative diseases. Get the poster here! https://t.co/66kxkeDTL1
#Alzheimers#Parkinsons#ClinicalTrials#Neuroscience
Join our Chief Scientist for her poster "Novel Digital Measures of Reaction Time and Drawing Speed" from the @ideafastproject. Discover how our digital tools can provide unique insights into movement & accuracy in neurodegenerative disorders: https://t.co/ygPwyFPS5q